
KTTA Stock Forecast & Price Target
KTTA Analyst Ratings
Bulls say
Pasithea Therapeutics is well-positioned for success in the biotechnology industry with its innovative drug pipeline and focus on treating CNS disorders. The potential for market growth and positive early results from clinical trials make this stock a strong investment opportunity. The company's diverse portfolio and strong financial standing further support a positive outlook for the stock and its potential to provide significant returns for investors.
Bears say
Pasithea Therapeutics is a newly incorporated biotechnology company that has recently completed an IPO and has a focus on developing new treatments for MAPK pathway-driven tumors, psychiatric and neurological disorders, and neurological diseases. However, the company is still in its early stages and is heavily reliant on future clinical trial success and partner collaborations for profitability. Additionally, the company has a high level of competition within the NF1 market and faces significant financing and commercial risks in the future.
This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.
KTTA Analyst Forecast & Price Prediction
Start investing in KTTA
Order type
Buy in
Order amount
Est. shares
0 shares